Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy plus /- oral agents in type 2 diabetes

Bibliographic Details
Main Authors:	Matthews, DR, Fulcher, G, Perkovic, V, de Zeeuw, D, Mahaffey, K, Rosenstock, J, Davies, M, Capuano, G, Desai, M, Shaw, W, Vercruysse, F, Meininger, G, Neal, B
Format:	Journal article
Published:	2012

Similar Items